Eden Research Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Eden Research şirketinin toplam hissedar öz sermayesi £12.7M ve toplam borcu £0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla £15.0M ve £2.3M dir.

Anahtar bilgiler

Borç/özkaynak oranı

UK£0

Borç

Faiz karşılama oranı	n/a
Nakit	UK£4.95m
Eşitlik	UK£12.71m
Toplam yükümlülükler	UK£2.32m
Toplam varlıklar	UK£15.03m

Son finansal sağlık güncellemeleri

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 9T7 'nin kısa vadeli varlıkları ( £8.7M ) kısa vadeli yükümlülüklerini ( £2.3M ) aşıyor.

Uzun Vadeli Yükümlülükler: 9T7 şirketinin kısa vadeli varlıkları ( £8.7M ) uzun vadeli yükümlülüklerini ( £19.6K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 9T7 borçsuzdur.

Borcun Azaltılması: 9T7 un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 9T7 şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: 9T7, serbest nakit akışı her yıl % 14.8 oranında tarihi oranda azalmaya devam ederse 3 yıldan fazla bir süre yeterli nakit akışına sahip olur

Eden Research Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Eden Research Delists from the OTCQB Exchange in the US

Recent updates

New major risk - Financial position

Eden Research Delists from the OTCQB Exchange in the US

First half 2024 earnings released: UK£0.002 loss per share (vs UK£0.015 loss in 1H 2023)

Eden Research plc to Report First Half, 2024 Results on Sep 23, 2024

Eden Research plc Announces Temporary Approval for Cedroz in Greece

Eden Research plc Announces Executive Changes

Eden Research plc Announces Biofungicide Regulatory Authorisation in Germany

Eden Research plc Announces Appointment of Daniel Mulas García as Global Product and Marketing Lead

Eden Research plc Announces Biofungicide Label Extension in Spain

Eden Research plc Appoints Humair Tariq as New Global Commercial Lead

Full year 2023 earnings released: UK£0.015 loss per share (vs UK£0.006 loss in FY 2022)

Eden Research plc to Report Fiscal Year 2023 Results on May 07, 2024

Eden Research plc Announces Appointment of Derek Mcallan as Non-Executive Director and as Chairman of the Audit Committee Following the Company's 2024 AGM

New major risk - Revenue and earnings growth

Full year 2023 earnings released: UK£0.015 loss per share (vs UK£0.006 loss in FY 2022)

New minor risk - Financial data availability

Insufficient new directors

Eden Research plc Announces Richard Horsman to Stepped Down as Non-Executive Director

Eden Research plc Provides Revenue Guidance for the Full Year of 2023

First half 2023 earnings released: UK£0.015 loss per share (vs UK£0.003 loss in 1H 2022)

Eden Research plc to Report First Half, 2023 Results on Sep 29, 2023

New major risk - Revenue and earnings growth

New minor risk - Shareholder dilution

Eden Research plc Announces Regulatory Application for Authorised Use of Ecovelex™ in the United Kingdom

Eden Research plc, Annual General Meeting, Jun 29, 2023

Full year 2022 earnings released: UK£0.006 loss per share (vs UK£0.007 loss in FY 2021)

Eden Research plc to Report Fiscal Year 2022 Results on May 05, 2023

Eden Research plc Announces First Mevalone Authorisation for Domestic Use

Eden Research plc Provides Revenue Guidance for the Full Year of 2022

Less than half of directors are independent

First half 2022 earnings released: EPS: UK£0 (vs UK£0.004 loss in 1H 2021)

Eden Research plc Grants US EPA Regulatory Approval

Eden Research plc Appoints Richard Horsman as Non-Executive Director, with effect from 1 September 2022

Eden Research plc, Annual General Meeting, Jun 29, 2022

Full year 2021 earnings released: UK£0.007 loss per share (vs UK£0.007 loss in FY 2020)

Eden Research plc Announces Progress Towards EPA Approval and Further Authorisation in Italy

Insufficient new directors

First half 2021 earnings released: UK£0.004 loss per share (vs UK£0.004 loss in 1H 2020)

Eden Research plc Announces New Label Extension for Biofungicide in Portugal

Full year 2020 earnings released: UK£0.007 loss per share (vs UK£0.005 loss in FY 2019)

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin